Abstract: The invention provides mutated IgG2 constant regions and anti-CD3 antibodies incorporating the same. Such antibodies specifically bind to the CD3 antigen on T-cells but induce reduced mitogenic response compared with otherwise identical antibodies bearing natural IgG2 constant regions. The antibodies can be used for treating disorders requiring immune suppression with fewer side effects than result from treatment with prior anti-CD3 antibodies.
Type:
Grant
Filed:
May 31, 1996
Date of Patent:
November 10, 1998
Assignee:
Protein Design Labs, Inc.
Inventors:
J. Yun Tso, Michael S. Cole, Claudio Anasetti